Coverage
-
August 01, 2023
AstraZeneca has set aside $510 million to resolve Bristol-Myers Squibb Co.'s litigation that it infringed cancer treatment patents to create rival immunotherapy drugs, according to a recent securities filing.
1 other articles on this case.
View all »